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ABSTRACT
Menopausal disorders may include shorter-term symptoms, such as hot flushes and night sweats (vaso-
motor symptoms, VMS) and longer-term chronic conditions such as cardiovascular disease (CVD),
osteoporosis, and cognitive impairment. Initially, no clear link between the shorter-term symptoms and
longer-term chronic conditions was evident and these disorders seemed to occur independently from
each other. However, there is a growing body of evidence demonstrating that VMS may be a bio-
marker for chronic disease. In this review, the association between VMS and a range of chronic post-
menopausal conditions including CVD, osteoporosis, and cognitive decline is discussed. Prevention of
CVD in women, as for men, should be started early, and effective management of chronic disease in
postmenopausal women has to start with the awareness that VMS during menopause are harbingers
of things to come and should be treated accordingly.
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Introduction
The 20th century witnessed a major epidemiologic transition
characterized by a shift in the leading causes of death from
infectious diseases to chronic conditions1. Life expectancy at
birth now exceeds 80 years in many countries, which means
that many women spend over a third of their lives in a post-
menopausal state and one in every two women will experience
about 30 years of postmenopausal life. Menopause frequently
coincides with the period when women are at the peak of
their careers and, because women are postponing pregnancy
until later in life, many will also have young children. Although
the menopause is a natural transition, it has important physio-
logical manifestations resulting from hormonal changes that
have far-reaching short- and long-term consequences.
In general, menopausal disorders can be divided into two
main groups: short-term symptoms, the most common of
which are hot flushes and night sweats known as vasomotor
symptoms (VMS) and longer-term chronic conditions includ-
ing cardiovascular disease (CVD), osteoporosis, and cognitive
impairment2. For many years, it was thought that short-term
symptoms and long-term chronic conditions occurred inde-
pendently with no causal link between them. However, there
is now a body of evidence demonstrating that menopausal
symptoms, in particular VMS, may be considered precursors
or biomarkers of chronic disease.
In this Expert Opinion piece, a multidisciplinary group of
Italian physicians, involved in the care of postmenopausal
women, review and discuss the evidence and emerging find-
ings for the link between VMS in menopause and a range of
chronic postmenopausal conditions including CVD, osteopor-
osis, and cognitive decline.
Vasomotor symptoms: more than a nuisance
Of the core symptoms that make up the menopause, VMS
(hot flushes or night sweats) are the most frequently
reported, and most women experience VMS at some stage
during the menopausal transition. In the Study of Women’s
Health Across the Nation (SWAN), one of the largest con-
ducted in menopausal women, 60–80% of women experi-
enced VMS during the menopausal transition3. A sizable
portion of women report VMS earlier in midlife, before the
onset of menstrual cycle changes, which continued for many
years postmenopause4,5. VMS occur more frequently in
women with premature menopause (occurring before the
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with medically induced premature menopause (induced by
oophorectomy, chemotherapy, or radiotherapy) may experi-
ence more severe symptoms6. The long-term consequences
of premature or early menopause include adverse effects on
cognition, mood, CVD, bones, and sexual health, as well as
an increased risk of early mortality7. In fact, the 2016 IMS
Recommendations on women’s midlife health outline that
women with POI should receive hormonal treatment after
exclusion of contraindications to prevent an increase in the
risk of cardiovascular disease, osteoporosis, cognitive decline,
dementia and Parkinsonism [Grade B recommendation]8.
Hot flushes impair quality of life, disturb sleep, and have a
negative effect on mood2,3,9. Untreated hot flushes are associ-
ated with higher health-care utilization, work loss, and total
costs. Sarrel and colleagues compared over a quarter of a mil-
lion (252273) women with hot flushes with an equal number
of matched control women without hot flushes and found
that women with hot flushes made 1.5 million more patient
visits than those without10,11. Untreated VMS were associated
with a significantly higher frequency of outpatient visits and
incremental direct and indirect costs. Furthermore, a recent
study overturned the long-held belief that VMS last for a rela-
tively short time (<2 years after the final menstrual period).
Avis and colleagues showed that frequent VMS lasted in
excess of 7 years for more than half of women in the SWAN,
persisting for 4.5 years after the final menstrual period12. VMS
can last for decades, and as such should be taken into
account when making treatment decisions. For the purpose of
this review, VMS are included in the ‘short-term symptoms’
category, but it should be remembered that they are anything
but short-term in a significant percentage of women. Results
of a population-based, cross-sectional study in 1548 older
Australian women (aged 65–79 years) showed that VMS were
common, but predominantly untreated, and the highest
prevalence of VMS (39.2%; 95% confidence interval (CI)
35.4–43.2) was seen for women aged 65–69 years13.
The physiology of hot flushes is not completely under-
stood. VMS are thought to be endocrine and/or thermo-
regulatory events originating in the hypothalamus as the
result of decreases in ovarian hormones. The fundamental
role of estrogen deprivation is well known and underlined by
the recent Global Consensus Statement on Menopausal
Hormone Therapy stating that hormonal therapy, including
tibolone and the combination of conjugated equine estro-
gens and bazedoxifene, is the most effective treatment for
VMS associated with menopause at any age14.
Women with severe hot flushes may have an increased
sympathetic tone with vascular involvement15. What is, how-
ever, now clear is that hot flushes (previously thought to be
solely due to decreased estrogen levels) are a complex multi-
causal phenomenon and reflect a combination of intercon-
nected systems including genetic bases, diet, physical
changes, use of medications, cultural influences, and individ-
ual experiences and expectations16–18.
Cardiovascular disease in women
World-wide, 8.6 million women die from heart disease each
year, accounting for a third of all deaths in women19.
Historically, CVD was considered a male disease; however,
since 1984, more women than men have died each year
from heart disease and the gap between men and women’s
survival continues to widen19. In the USA, 267 000 women
die each year from heart attacks, which kill six times as many
women as breast cancer19. Likewise, in Europe, CVD is the
leading cause of death and, despite recent decreases in mor-
tality rates in many countries, it is still responsible for over
4 million deaths per year, with the proportion of deaths
attributable to CVD greater in women (51%) than in men
(42%)20. Because women have a longer life expectancy, larger
numbers of older women mean that the absolute number of
deaths due to CVD in women is actually rising and nearly
half of all deaths in women over 50 years are due to some
form of CVD21,22.
Paradoxically, despite being the leading cause of death, per-
sisting cultural misperceptions and lack of effective manage-
ment of risk factors mean that CVD is frequently undetected
and untreated in women, with fatal consequences. The proc-
esses involved in CVD start long before their clinical manifest-
ation and it is important to begin to manage risk factors
during the ‘window of opportunity’ to maximize reductions in
CVD and overall mortality23. Effective primary prevention is
therefore a critical health-care priority as stated by the most
recent International Menopause Society guidelines8.
The Framingham study provided evidence of the relation-
ship between menopause and cardiovascular mortality, with
a 103% increased risk of ischemic stroke in women who
experienced natural menopause before the age of 42 com-
pared with women with later menopause, and a trend of
increasing risk of ischemic stroke with decreasing age at the
time of natural menopause24. The study conducted in 2873
women who were followed for 24 years showed that no pre-
menopausal woman developed a myocardial infarction or
died from CVD, but that CVD in postmenopausal women was
more than doubled that in premenopausal women (20 vs. 70
cardiovascular events)25,26. Similarly, the Nurses’ Health Study
including 121 700 females showed that, after adjusting for
age, CVD risk among women with a natural menopause was
increased compared with the risk among premenopausal
women27. Women who had surgical menopause (bilateral
oophorectomy) and did not use hormone replacement ther-
apy were found to be at increased risk of coronary heart
disease (CHD) compared with age-matched controls (risk
ratio 2.2)27.
Epidemiological studies of age at menopause and CHD
have shown that women experiencing early menopause
(between age 40 and 45 years) have an increased risk of
future CVD, with one study showing a two-fold increased risk
of CHD or ischemic stroke28,29. Shuster and colleagues
reviewed the literature and concluded that data show an
increased risk for CVD in women who undergo bilateral
oophorectomy, inducing premature (age <40 years) or early
(age 40–45 years) menopause7. Women with a natural pre-
mature menopause (<40 years) had a 2-year lower life
expectancy compared with women with a normal or late
menopause30.
Cardiovascular aging is not the same in men and women.
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age of 45 years, whereas in women the risk is 2–3 times
higher after menopause (whether early or late, natural or sur-
gically induced)31. It is not clear whether there is an inverse
causality between early menopause and CVD. On the one
hand, ovarian exhaustion in women who have an early
menopause may occur as a result of an unfavorable cardio-
metabolic profile; on the other hand, it may be that ovarian
exhaustion causes premature atherosclerosis of the ovarian
vessels, thus impairing their function. To understand the eti-
ology and evolution of CVD in women, a complete hormonal
picture starting from menarche, through pregnancy, until
menopause needs to be considered.
In a 2016 robust meta-analysis including 32 studies with
310 329 non-overlapping women, the role of menopause in
CVD was clearly demonstrated32. In particular, premature or
early-onset menopause in women younger than 45 years was
associated with an increased risk of coronary artery disease
and all-cause mortality. The relative risks (95% CIs) were 1.50
(1.28–1.76) for overall CHD, 1.11 (1.03–1.20) for fatal CHD,
1.23 (0.98–1.53) for stroke overall, 0.99 (0.92–1.07) for stroke
mortality, 1.19 (1.08–1.31) for CVD mortality, and 1.12
(1.03–1.21) for all-cause mortality. In addition, in comparison
with women who experienced menopause before the age of
50 years, those who were aged 50–54 years at the onset of
menopause showed a decreased risk of fatal CHD (relative
risk 0.87; 95% CI 0.80–0.96) and no effect on stroke.
Menopause, vasomotor symptoms, and
cardiovascular disease
Current cardiovascular risk algorithms do not predict well for
clinical CVD in middle-aged women and a better understand-
ing of the role played by VMS in vascular health could help
identify women with an increased risk. Women with VMS
have less favorable cardiovascular markers than those with-
out symptoms. In one study, in over 11 000 women (aged
45–50 years), those having frequent VMS had an increased
risk of developing CHD over 14 years, even when the effects
of age, menopause status, lifestyle, and other chronic disease
risk factors were taken into account17. The SWAN and its fol-
low-up, in an older cohort of women, showed that women
with hot flushes had indices of greater subclinical CVD,
including poorer endothelial function and poorer flow-
mediated dilation (FMD), and greater aortic calcification, and
intima media thickness than women without hot flushes33,34.
Others have found similar findings for endothelial function35.
The vascular endothelium regulates blood viscosity and
coagulation, and vagal stimulation can weaken procoagulant
responses to endotoxin. Hot flushes are also associated with
a lower level of total plasma antioxidant activity and an
increased cardiovascular response to stressful situations36.
Vascular aging, endothelial dysfunction, and large artery stiff-
ening seem to increase in women during the menopausal
transition. It may be that the menopause acts as a trigger to
decreased vascular function and increased vascular vulner-
ability as women age. It has been shown that, during the
perimenopausal period, reduced ovarian function and
decreased estrogen levels accelerate vascular aging37.
Although more work needs to be done to elucidate the exact
mechanisms leading to endothelial dysfunction and large
artery stiffening, it has been suggested that a combination of
oxidative stress, vascular inflammation, estrogen receptor
alpha, and endothelial NOS dysfunction contribute to the
process37.
Analysis of the SWAN subgroup showed that VMS, particu-
larly frequent hot flushes, were associated with increases in
tissue plasminogen activator antigen (tPA-ag), and factor
VIIc38. Altered inflammation and hemostasis have been
related to CVD risk, and the endothelium (dysfunction of
which has been linked to VMS) plays a central role in regulat-
ing blood coagulation and inflammation. Important add-
itional findings from the SWAN show that hot flushes were
associated with elevated factor VIIc (an important protein in
the coagulation cascade) and tPA-ag (a fibrolytic protein
largely derived from the endothelium and associated with
elevated cardiovascular risk among women) after multivari-
able adjustment. The results suggest an association with
hemostatic, as opposed to inflammatory processes but,
because inflammatory and hemostatic processes are interre-
lated and several of the markers have both roles, the authors
recommend caution in interpreting the results38.
In the Women's Ischemia Syndrome Evaluation Study
(WISE), endothelial function determined by brachial artery
FMD, was assessed in 104 postmenopausal women (>50
years) with signs/symptoms of ischemia39. Receiver-operating
curve analysis was used to determine VMS groups: symptoms
beginning at age <42 years (early onset), beginning at 42
years (later onset), and never, which were examined in rela-
tion to cardiovascular events and FMD. Women who had
VMS when they were young (42 years) had significantly
lower FMD compared with women whose symptoms started
after the age of 42 years (p¼ 0.038) and those who never
had VMS. The MS Heart study enrolled 189 women (non-
smokers, intact uterus and ovaries, not using hormones)
aged 40–60 years, without heart disease40. There was a sig-
nificant relationship between hot flushes and FMD and age
(p¼ 0.03). In younger women (<52 years), a higher number
of hot flushes was associated with lower FMD (p¼ 0.02). FMD
in younger women who had 10 hot flushes a day was
reduced by almost half compared with younger women with-
out hot flushes, indicating that the more hot flushes these
women had, the more evidence of endothelial dysfunction
and CVD risk there was.
Silveira and colleagues reported an inverse correlation
between the intensity of hot flushes and postreactive hyper-
emia flow in two groups of women: those with recent
(<10 years) and late (>10 years) menopause41. In both
groups, hot flushes were associated with endothelial dys-
function and higher systolic and diastolic blood pressures,
but the relationship between hot flushes and endothelial
dysfunction was independent of blood pressure. Endothelial
dysfunction, if not treated, may progress to atherosclerosis
with subsequent increase in risk of myocardial infarction or
stroke, currently the major causes of death in postmeno-
pausal women41.
Menopause and aging induce variations of some cardio-
























































































































in a sex-specific manner. Campesi and colleagues analyzed
markers of oxidative stress, systemic inflammation, and endo-
thelial dysfunction in men younger and older than 45 years
and in pre- and postmenopausal women42. They reported
that, before body weight correction, men overall had higher
creatinine, red blood cells, and hemoglobin and lower trigly-
cerides than women. Men younger than 45 years had lower
levels of tumor necrosis factor (TNF)-a and malondialdehyde
and higher levels of arginine than age-matched women,
whereas postmenopausal women had higher interleukin (IL)-
6 concentrations than men, and higher total cholesterol, tri-
glycerides, creatinine, and IL-6 levels than younger women.
Oxidative stress, inflammation, and endothelial dysfunction
were associated with aging/menopause status for women
and aging for men. Aging/menopause status increased many
more cardiovascular risk factors in women than aging in
men, confirming that postmenopausal women had increased
vascular vulnerability and indicating the need for early car-
diovascular prevention in women42. VMS occurring early in
the menopausal transition were not associated with
increased CVD risk whereas late VMS were associated with
increased CHD risk and all-cause mortality43. It is not known
whether VMS occurring for the first time in late menopause
are pathophysiologically distinct from classic perimenopausal
VMS. There also appears to be a link (via the sympathetic
nervous system) between VMS and high blood pressure in
menopausal women, with those with hot flushes having a
significantly higher incidence of essential hypertension and
high systolic blood pressure than those without hot
flushes44,45. Collins and colleagues, in a review published in
2016, discussed current knowledge of the importance of con-
ventional CVD risk factors (smoking, hypertension, lipids, and
diabetes mellitus) as well as the link between VMS and CVD
risk23. They also discussed how menopausal VMS are associ-
ated with increased sympathetic and decreased parasympa-
thetic function that may increase the risk of cardiovascular
events, which may be particularly important during a hot
flush episode in women with a propensity to severe
arrhythmias23.
Cagnacci and colleagues, in a series of studies, investi-
gated the association between menopausal symptoms and
CVD risk factors46–49. One studied the relationship between
oxidative stress and climacteric symptoms in 50 apparently
healthy postmenopausal women47. Results showed that
blood antioxidant defense is mainly determined by climac-
teric complaints and, among the possible endocrine, meta-
bolic, and body parameters, it was only climacteric
symptoms (not high density lipoprotein cholesterol or other
metabolic parameters) that were linearly related to the
decrease of antioxidant defenses.
Oxidative stress is a risk factor for CVD and these data
provide additional evidence of the causal link between VMS
and CVD. In another study by the same group, the Greene
Climacteric Scale score was associated with raised 24-h urin-
ary cortisol levels49. The Greene Climacteric Scale is com-
posed of 21 items that evaluate VMS (two items), anxiety (six
items), depression (five items), somatic symptoms (seven
items), and sexuality (one item). An increased cortisol level is
believed to play an important role in the aging process as
well as having a detrimental effect on the immune response.
There is evidence that it is involved in degeneration of
hippocampus neurons, impairs memory and cognitive func-
tion, and accelerates bone loss as well as promoting the
metabolic syndrome and diabetes, which in turn increase the
risk for atherosclerosis/CVD.
Two large-scale meta-analyses assessing the association of
VMS with various cardiovascular risk markers in tens of thou-
sands of perimenopausal, menopausal, and postmenopausal
women were recently published50,51. In general, results
showed that women with VMS have an unfavorable cardio-
vascular risk profile (increased risk of CVD, CHD, or ischemic
stroke) compared with women without VMS. Women experi-
encing VMS have significantly higher systolic and diastolic
blood pressures, higher circulating total cholesterol levels,
and a higher body mass index than their counterparts with
no symptoms. There was also a positive, albeit weak, associ-
ation of VMS with hypertension.
Menopause, vasomotor symptoms, and
osteoporosis
Postmenopausal osteoporosis affects up to 200 million
women world-wide with 70% of hip fractures occurring in
women52,53. Osteoporotic fractures can lead to chronic pain,
deformity, depression, disability, and death as well as having
huge economic consequences. In the UK alone, annual hos-
pital costs associated with hip fractures are estimated to be
£1.1 billion54. The prevention of fractures in postmenopausal
women is, therefore, a vital public health priority world-
wide52,53.
The observation that VMS peak around the same time as
accelerated bone loss has led researchers to examine
whether there was a link between VMS and adverse bone
health55–66. However, it was not until 2015 that the first pro-
spective study in a large cohort of postmenopausal women
was conducted67. The study analyzed the medical records of
more than 23 000US women (aged 50–79 years). Results
showed that women with moderate/severe VMS had lower
bone mineral density (at the femoral neck and lumbar spine)
and increased rates of hip fractures during more than 8 years
of follow-up compared with women who did not have
VMS67. These results confirmed those of Gast and colleagues,
who showed that VMS were associated with reduced bone
density57.
Lower estradiol levels in women with hot flushes may
explain the associations between VMS and reduced bone
density. During menopause, reduced hormone levels are
linked to increases in serum levels of inflammatory cytokines
(TNF-a, IL-4, IL-10, and IL-12) – cytokines that stimulate osteo-
clast and osteoblast formation, leading to increased bone
turnover and eventually bone loss68. The mechanisms
involved in the association between VMS and osteoporosis
are complex, but it may be that, in menopause, decreases in
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the proinflammatory cytokines lead to oxidative stress and
ultimately loss of bone density69.
Menopause, vasomotor symptoms, and cognitive
function
Women have long reported ‘brain fog’ or memory problems
during menopause. As well as the short-term implications on
work and everyday activities, women worry that these symp-
toms may be linked to future cognitive impairment – demen-
tia is more common in women than men (16% vs. 11% aged
>71 years). It is therefore important to understand the mech-
anisms mediating cognitive decline in women. In the SWAN,
over 40% of perimenopausal and postmenopausal women
reported that they suffered from forgetfulness/worsening
memory compared with 31% of premenopausal women70,
whereas in the Seattle Midlife Women’s Health Study that
enrolled women between the ages of 35 and 55 years, over
60% of midlife women reported an undesirable change in
memory71.
Postmenopausal women have low levels of estrogens and
these are linked with both cognitive changes and inflamma-
tion72. It appears that estrogens, via their effects on the
hippocampus and prefrontal cortex, play a significant role in
cognitive functioning73–76. Premenopausal women showed
higher achievements in verbal memory performance during
the phases of the menstrual cycle associated with high estro-
gen2. However, it is likely that these changes are multifactor-
ial with the hallmark symptoms of menopause (depression,
sleep disturbance, and hot flushes) playing independent or
synergistic roles77.
There are few studies directly addressing the relationship
between hot flushes and cognitive performance; however, a
study by Maki and colleagues in 29 peri- and postmeno-
pausal women (mean age 53 years) showed that objective,
rather than subjective (highly symptomatic women underre-
port the number of objective hot flushes by 43%) hot flushes
impaired verbal memory in women with moderate to severe
VMS. Interestingly, changes in memory appeared to be due
to night-time rather than daytime hot flushes. These findings
suggest that physiological, rather than psychological, factors
associated with VMS relate to memory dysfunction in the
menopause transition76,78.
In a similar study by the same group in 68 menopausal
women (mean age 53 years), the frequency of hot flushes
was significantly related to performance on a test of episodic
memory79. There is evidence that estrogen, and its estrogen
receptor alpha isoform, exert their protective effect by acting
as neuro-anti-inflammatories – when estrogen levels are
reduced, such as in menopause, neuro-inflammatory proc-
esses persist. Estrogen in the microglia might influence the
onset and progression of neurodegenerative diseases80.
Although inflammation has been put forward as one of the
potential mediators between low levels of estrogen and cog-
nitive function, Maki and colleagues proposed that cortisol
might mediate the relationship between objective hot flushes
and cognitive performance in highly symptomatic women78.
Levels of cortisol increase after hot flushes, and menopausal
women with high levels of urinary cortisol are more likely to
have severe hot flushes compared with those with lower cor-
tisol levels. Several days of exposure to cortisol, at doses and
plasma concentrations associated with physical and psycho-
logical stress in humans, reversibly decreased specific ele-
ments of memory performance in otherwise healthy
individuals81.
Conclusions
The climacteric syndrome, mainly, but not only, related to
estrogen deprivation, leads most women to seek medical
advice and this is an opportunity to provide support and
implement therapy strategies. It is important that women are
not left to ‘suffer in silence’ but are provided with up-to-date
information on the long- as well as short-term implications of
not treating menopausal symptoms in general and VMS in
particular. The effective management of chronic disease in
postmenopausal women starts with the awareness that VMS
during menopause are harbingers of things to come and
should be managed accordingly.
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